Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.35 USD | -0.74% | +3.05% | +15.38% |
13/05 | HC Wainwright Adjusts Price Target on Clearside Biomedical to $5 From $6, Keeps Buy Rating | MT |
09/05 | Transcript : Clearside Biomedical, Inc., Q1 2024 Earnings Call, May 09, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+15.38% | 10Cr | |
+12.30% | 12TCr | |
+12.15% | 11TCr | |
-8.14% | 2.34TCr | |
-1.69% | 2.18TCr | |
-10.60% | 1.81TCr | |
-41.25% | 1.67TCr | |
-15.33% | 1.6TCr | |
+5.80% | 1.4TCr | |
+28.03% | 1.17TCr |
- Stock Market
- Equities
- CLSD Stock
- News Clearside Biomedical, Inc.
- Clearside Biomedical Retinal Disease Treatment Candidate Meets Primary Endpoint in Phase 1/2a Trial